Pamela S Douglas1, Rebecca T Hahn2, Philippe Pibarot3, Neil J Weissman4, William J Stewart5, Ke Xu6, Zuyue Wang7, Stamatios Lerakis8, Robert Siegel9, Christopher Thompson10, Deepika Gopal11, Martin G Keane12, Lars G Svensson5, E Murat Tuzcu5, Craig R Smith2, Martin B Leon2. 1. Duke Clinical Research Institute and Duke University Medical Center, Durham, North Carolina. Electronic address: pamela.douglas@duke.edu. 2. Columbia University Medical Center/New York Presbyterian Hospital, New York, New York. 3. Department of Medicine, Laval University, Quebec, Quebec, Canada. 4. Medstar Health Research Institute and Georgetown University School of Medicine, Washington, District of Columbia. 5. Cleveland Clinic Foundation, Cleveland, Ohio. 6. Cardiovascular Research Foundation, New York, New York. 7. Medstar Washington Hospital Center, Washington, District of Columbia. 8. Emory University School of Medicine, Atlanta, Georgia. 9. Cedars-Sinai Medical Center, Los Angeles, California. 10. St Paul's Hospital, Vancouver, British Columbia, Canada. 11. The Heart Hospital Baylor, Scott and White Health, Plano, Texas. 12. Temple Heart and Vascular Center, Philadelphia, Pennsylvania.
Abstract
BACKGROUND: Inoperable aortic stenosis may be treated with either transcatheter aortic valve replacement (TAVR) or medical management (MM) with or without balloon aortic valvuloplasty (BAV). The aim of this study was to compare the long-term echocardiographic findings among TAVR, MM, and BAV in patients with severe, inoperable aortic stenosis. METHODS: A total of 358 inoperable patients in the Placement of Aortic Transcatheter Valves trial were randomized to MM or TAVR. Echocardiograms obtained at baseline, 30 days, and 1, 2, and 3 years were analyzed by a central core laboratory. RESULTS: At baseline, TAVR and MM were similar, with more frequent Society of Thoracic Surgeons score > 10 (51.7% vs 65.0%, P = .03) and larger end-systolic volumes (54.5 ± 29.3 vs 69.1 ± 48.0 mL, P = .03) in MM. By 30 days after TAVR, mean aortic valve gradient had decreased (from 43.8 ± 14.7 to 10.0 ± 4.3 mm Hg, P < .001), ejection fraction had increased (from 53.2 ± 12.4% to 56.7 ± 10.0%, P < .001), and left ventricular (LV) mass index had decreased (from 144.7 ± 36.1 to 140.0 ± 37.9 gm/m(2), P < .05). After 1 year, aortic valve gradients and area were unchanged, while LV mass index had decreased by another 16 gm/m(2) (to 124 gm/m(2)). By 30 days after BAV, mean aortic valve gradient had decreased from 43.4 ± 15.0 to 31.9 ± 11.1 mm Hg, while ejection fraction and LV mass index were unchanged; gradient reverted to baseline at 1 year. No changes in gradients or mass were seen in MM patients. CONCLUSIONS:TAVR results in immediate and sustained relief in pressure overload and improved LV systolic function, with continued regression of hypertrophy over 3 years. Poor clinical results with BAV are explained by the modest and transient reductions in pressure overload with BAV, which were not accompanied by improved LV function or remodeling. TAVR is the preferred treatment in eligible inoperable patients (ClinicalTrials.gov identifier NCT00530894).
RCT Entities:
BACKGROUND: Inoperable aortic stenosis may be treated with either transcatheter aortic valve replacement (TAVR) or medical management (MM) with or without balloon aortic valvuloplasty (BAV). The aim of this study was to compare the long-term echocardiographic findings among TAVR, MM, and BAV in patients with severe, inoperable aortic stenosis. METHODS: A total of 358 inoperable patients in the Placement of Aortic Transcatheter Valves trial were randomized to MM or TAVR. Echocardiograms obtained at baseline, 30 days, and 1, 2, and 3 years were analyzed by a central core laboratory. RESULTS: At baseline, TAVR and MM were similar, with more frequent Society of Thoracic Surgeons score > 10 (51.7% vs 65.0%, P = .03) and larger end-systolic volumes (54.5 ± 29.3 vs 69.1 ± 48.0 mL, P = .03) in MM. By 30 days after TAVR, mean aortic valve gradient had decreased (from 43.8 ± 14.7 to 10.0 ± 4.3 mm Hg, P < .001), ejection fraction had increased (from 53.2 ± 12.4% to 56.7 ± 10.0%, P < .001), and left ventricular (LV) mass index had decreased (from 144.7 ± 36.1 to 140.0 ± 37.9 gm/m(2), P < .05). After 1 year, aortic valve gradients and area were unchanged, while LV mass index had decreased by another 16 gm/m(2) (to 124 gm/m(2)). By 30 days after BAV, mean aortic valve gradient had decreased from 43.4 ± 15.0 to 31.9 ± 11.1 mm Hg, while ejection fraction and LV mass index were unchanged; gradient reverted to baseline at 1 year. No changes in gradients or mass were seen in MM patients. CONCLUSIONS: TAVR results in immediate and sustained relief in pressure overload and improved LV systolic function, with continued regression of hypertrophy over 3 years. Poor clinical results with BAV are explained by the modest and transient reductions in pressure overload with BAV, which were not accompanied by improved LV function or remodeling. TAVR is the preferred treatment in eligible inoperable patients (ClinicalTrials.gov identifier NCT00530894).
Authors: Nicholas Chew; Jimmy Kim Fatt Hon; Wei Luen James Yip; Siew Pang Chan; Kian-Keong Poh; William Kok-Fai Kong; Kristine Leok Kheng Teoh; Tiong Cheng Yeo; Huay Cheem Tan; Edgar Lik Wui Tay Journal: Singapore Med J Date: 2016-08-12 Impact factor: 1.858
Authors: Mona Malek Mohammadi; Aya Abouissa; Isyatul Azizah; Yinuo Xie; Julio Cordero; Amir Shirvani; Anna Gigina; Maren Engelhardt; Felix A Trogisch; Robert Geffers; Gergana Dobreva; Johann Bauersachs; Joerg Heineke Journal: JCI Insight Date: 2019-07-23
Authors: Kimi Sato; Arnav Kumar; Brandon M Jones; Stephanie L Mick; Amar Krishnaswamy; Richard A Grimm; Milind Y Desai; Brian P Griffin; L Leonardo Rodriguez; Samir R Kapadia; Nancy A Obuchowski; Zoran B Popović Journal: J Am Heart Assoc Date: 2017-07-11 Impact factor: 5.501
Authors: Johannes Patzelt; Miriam Ulrich; Annika Becker; Karin A L Müller; Rezo Jorbenadze; Michal Droppa; Wenzhong Zhang; Sarah Mandel; Lisa Habel; Henning Lausberg; Janine Pöss; Tobias Geisler; Oliver Borst; Peter Rosenberger; Christian Schlensak; Meinrad Gawaz; Jürgen Schreieck; Peter Seizer; Harald F Langer Journal: PLoS One Date: 2018-10-19 Impact factor: 3.240